Flerie AB (publ)

Good morning and welcome to FLIRI's Q3 report presentation with me, Ted Fjellman, and our CFO Cecilia Schiele. We're very excited to tell you about the advancing life science innovations from our portfolio and also to help explain our unique share redemption scheme that was introduced with our IPO three months ago. Before we do that, the usual disclaimer. And let me start before we go into the details about the Q3 report and just reminding those of you who may not know us so well of our way of working and also the fact that we have been around since 2011 and have a proven track record of 14% IRR per year. Just a reminder, we are a life science investment company. We're very active investors investing in a diversified portfolio of 29 companies using these four pillars on the left hand side, always taking a board seat and through that being active, also working with the CEO management teams on product roadmaps and also the expansion of their often platform technologies that are very widely applicable. And of course, building up this famous Fleary and Peers peer-to-peer network that we've had for many years now, really valued by the CEOs who get to exchange with each other and really learn from each other. And last but not least, the collaborations and the synergies that we try to establish to advance our both products and services on the market the most famous case of that being north x biologics than our manufacturing powerhouse not unlike the very early days of recifarm that our chairman thomas eldred built up we're now building up northex biologics and all many of our companies are working with northex let's move on to the q3 report details So, we have an active portfolio approach and it is delivering results. So, today I'll talk a little bit about the syndication and also the development progress that we've had during the quarter. First, the net asset value was almost 4.3 billion crowns, about 54.6 or precisely 54.59 crowns per share. This really shows that we are a top-tier European investment company with significant assets. We also have significant firepower after the IPO. We now have 911.3 million crowns in cash and cash equivalents. That actually represents 11.67 crowns per share out of the 54.59. So, actually, if you think about it, we really have quite a substantial 20% of NOV in cash, and we're deploying roughly 10% of NOV per year into mostly our current portfolio of 29 innovative companies. So what has happened during the quarter? We have very significantly catalyzed investment from other investors into three companies that I'm exemplifying here. We've also continued to syndicate with others to do that in future quarters in other companies. But in this quarter, Atrogi attracted 30 million crowns, Strike Pharma 12 million and Chromafora 40 million crowns and you can see in brackets how much flurry put in into each of those rounds so by no means if you take the total here are we the majority shareholder actually we catalyze 47.5 million crowns alongside our 34.5 so uh very happy about that and also very good syndicating partners who also know what they're doing and have a long-term view on building these companies significant value changes during the quarter um the first two are very positive lipum 66 million up scintilla 60 million up x-ray unfortunately went down to 173 million for in fleary's fair value so this is these all three of these companies are actually publicly listed companies that's where most of the volatility exists in our portfolio but we're very happy leapum who's actually moving on in their in their product development into phase two. I'm showing here, LiPo actually is a company that's working on rheumatoid arthritis. And rheumatoid arthritis is, of course, a big indication. They are having a new candidate, SOL116, that addresses several things that are not available to patients today. The last patient enrolled in this phase one study, and they successfully are developing the manufacturing for the next clinical trial together with NorthEx Biologics. So this is actually a very good example of this collaboration that we're doing. the bottom right hand side you can see that actually the fair value is 164 million and the capital invested that we've invested into leap room is 103 we own 57 of the company so it's one of the few actually only seven of our companies out of the 29 where we own more than 50 of the shares Synthiala is another company that's really gained on the stock market during the quarter, also publicly listed. You can see at the bottom right here again, the fair value, 165 million, where we've invested 91 million capital. Again, a company where we actually own more than 50%. It just happens to be that these companies are the ones we're mentioning during the quarter. Actually, this company is very exciting. Allogeneic stem cell-based treatments focusing both on osteoarthritis, so bone arthritis, and also difficult to treat leg ulcers. So these are wounds that just don't close up. And these stem cells, and they have a very specific way of selecting these stem cells, are able to help these wounds close and also help to build up bone mass in osteoarthritis patients. And last but not least, Expray, which of course many of you have been following separately, and of course all three of these companies you could technically invest in yourself. Expray had a second complete response letter from the FDA. What that means is the FDA provides feedback ahead of the commercialization in the USA. And of course it was disappointed to get this feedback, but actually the feedback is not around any fundamental issue with the pharmaceutical itself, it's actually around the labeling and the labeling comprehension by pharmacies and by doctors. So as you may know, if you follow X-Pray, X-Pray is developing a better version of an original drug called Spry-Cell, which is selling you know, it's a blockbuster drug by BMS. And this, of course, means that, you know, the payers, the pharmacies have to watch out to not give the same dose as Spry-Cell, because Exprase-Dacinoc is actually more potent. So, the FDA wanted more clearer labeling there, and that's what the company is working through now. There's actually only some delay here, but we really do believe in the company and that they will go to market in the US next year. Not only that, this technology can be applied to many protein kinase inhibitors. So, it's not just the Dazenoc and Spry cell market, but it's actually a lot more that X-ray could solve. Again, you see here the fair value, 294 million. We've invested 299 million. So, we're a long-term investor. We really believe that X-Ray will have that success that they deserve next year and beyond. other key developments in the private portfolio they don't affect our novice much but that's precisely because of our very prudent valuation methodology which our cfo is going to speak a little bit about later but just to point out the innovations that are advancing in our portfolio anacardio is a heart failure company In fact, today, all heart failure drugs are addressing the symptoms of heart failure, while Anacardio is actually developing a drug that will improve the contractility of the heart and help the pumping of blood. Very excited that they will be moving into phase two going forward. microbiotica just recently after the end of the quarter so beginning of this new quarter have dosed their first patient with their microbiome treatment both for melanoma and ulcerative colitis so welcome microbiotica to the clinical part of our portfolio And Amarna Therapeutics has received positive feedback on the development strategy for their type 1 diabetes gene therapy. Again, a very innovative technology here that allows tolerization in the future. It's really quite a unique technology that nobody else has and exemplifies what FLIRI does overall. We invest in really innovative products and companies that are developing them. So with that, I'll leave you to the numbers with Cecilia Schelle.

Thank you. So let's start by looking at the financial information in summary for the third quarter. Our net asset value was 4.262 billion end of September and 4.379 billion end of June. That's a decrease by almost 180 million in the quarter. Now per share was 54.59 sec as compared to 56.10 end of Q2. So that's a negative 2.7%. And when adjusted for the transaction cost that occurred from the reverse merger and the capital raise in June, equivalent to 1.3 sec per share, now per share in Q3 was 55.91%. Our portfolio fair value was 2.993 billion end of September as compared to 3.058 end of June, which is a decrease by 65 million or 4%. The decrease is due to value decreases of 121 million and investments in the portfolio in the quarter was 56. So we will shortly talk a bit more in detail of the value changes and the investments made in the quarter when we look at the segments. Net profit for the quarter was minus 117 million. And end of September, we had a cash balance of 911 million. And together with a loan facility, we have available more than 1 billion for future investments in our portfolio. And when we talk about NAV per share and NAV development, the single most important factor driving NAV development is of course the changes in the valuation of our portfolio companies. So for that, just a few words on our valuation methodology. We have a portfolio that consists of both listed and unlisted companies, and the listed companies are valued in accordance with the latest share price. Obviously, the private unlisted portfolio companies generally constituting around 75 percent of our portfolio are valued based on the latest financing round. So normally valuations are unchanged between financing rounds for the private companies. But we do adjust the valuation down if the company has, for instance, had a trial setback or is experiencing delays in sales growth. And since we sit on the board of all companies except one in accordance with our active ownership model, we have good knowledge of the company's progress or any issues that occur. And therefore, we can reduce the value when negative events happen. And also very important, when the company eventually is getting back on track, we can reverse the write-down back up to the value of the latest funding round of the previous valuation, but not higher. So we make reversals, but we don't increase the valuation. So let's look at the segments more in detail, if you go to the next slide. These are the three segments that Ted also outlined. If we start looking at the product development of the PD segment, which is our largest, End of September, it constitutes 77% of the total portfolio value and is split by 72% of private companies and 28% of listed companies. The fair value of the PD segment, the fair value of the portfolio at the end of the quarter was 2.354 billion. As compared to 2.365 at the beginning of the quarter, it's a decrease by 11 million. change in value of the segment in the quarter was minus 41 and as ted outlined just a couple of minutes ago the changes in value mainly come from the list company so x-ray with a decrease of 173 million in the quarter but also leap boom and they see that cynthia and other developed positively up by 66 and 60 million respectively and Just coming back to what I mentioned just on the valuations previously. In the quarter, there was also changes in the valuation of two of the private companies in the segment that were not to do with financing grounds. So starting with Epiendo, the fair value of our shares in Epiendo, we wrote down the fair value in Q1 already in full. And this was... due to the absence of efficacy results in the then ongoing phase 2 study. But after further analysis of the data and given that the study showed safety and tolerability as well as beneficial effects on inflammatory biomarkers, the decision was made to continue the development in the company And as the company now shows that the development is progressing and that there is a plan for continued operations that previously made right down was partially reversed in the quarter, resulting in a fair value increase of 55 million. And then on Viterra Biomedical, we decreased the value of our shares in the private company Viterra in the quarter by an additional 13 million. So that's a decrease. following a lower valuation in an upcoming funding round. So the round wasn't closed in the quarter, but since we had an approved term sheet, we chose to adjust the valuation accordingly. Investments in shares in the quarter for the PD segment was 30 million, of which the largest was Inga Trogi, 22 million and 6 million in Expray. If we continue to commercial growth of the CG segment, which is our second largest, constitutes 20% of the portfolio fair value end of September, and 93% of the segment fair value is private companies, and seven are listed companies, 7% of the fair value. The total fair value of the CG segment end of the quarter was 547 billion compared to 617 at the beginning of the quarters. It's a decrease by 70 billion. And the decrease is mainly due to a negative share price development in Nanologica that reduced or decreased 56 million in the quarter. And also an adjustment of the value of shares in A3P Biomedical to reflect the valuation of a couple of external share transactions, resulting in a decrease in fair value of 33 million. Investments in the quarter were 10 million in the segment, which is a follow-on investment in ChromaForum. And then briefly on the third segment, limited partnerships. It's the smallest of our segments, 3% in terms of our portfolio value, characterized by long-term commitments. We invested 16 million in the quarter in our funds, and the fair value, as you can see, was more or less unchanged. So this is about the financial performance. So let's continue with a couple of comments on the Fleury's share redemption program. Keep to the next slide. We provide a share redemption scheme in Swedish, where up to 5% of all the shares can be redeemed annually at the value of the latest number per share. The first conversion period will be in Q2 next year. In the following years, the conversion period will appear at Q1 instead. And some of our shareholders have agreed not to utilize this right. The majority owner, for instance, will not use the redemption scheme for several years. And the investors that participated in the directed issue in June are also exempt to participate in the first redemption. but they may participate in the other ones. So you will be able to redeem your shares at NAV per share, which gives you a really good opportunity, as it looks now. Our NAV, again, per share was 54.59, end of Q3, and the share price on the same day was 42.09, which means that at that day, our NAV per share exceeded the share price by 30%. And there are two main reasons for implementing the redemption scheme. And the first one is that to provide our shareholders a liquidity option. Some investors may need to realize liquidity to sell off part of their shares, even if they have invested with a long term perspective aligned with this long term active company building strategy. But the redemption scheme will provide for our shareholders a recurring liquidity option. And a certain one, since we have included the share redemption scheme in our articles of association. So it will not be taken out very easily. The second reason for the share redemption scheme was to align the share price and the reported number per share. So Florid is an active investor helping to build portfolio companies using special specialist experience and network. So build portfolio companies and build the value. And to support the market in understanding the added value that Fledi provides, in addition to, well, say only investing money, the redemption scheme should have the effect to reduce the current discount and to align the share price and the report in half per share. And although in the end, the market sets the price, once Fledi has become more known and there's overall confidence in the way we value our portfolio. There's no reason for why we shouldn't instead trade at a premium, we think. So all of you who want to read more about the detailed conditions for the scheme and the process for redemption, you can find this on our website, FII.com. So that wraps up the financial section. We'll hand back over to you, Ted.

Thank you, Cecilia. And just some concluding remarks from me. I'm showing you a slide here that really gives you the flavour of the diversified portfolio that we have. And we just exemplified a few companies during the quarter who had advances that are worth mentioning, but actually many more companies have advances. If you just look here, this is as of 30th of September, but I mentioned that Microbiotica, who here is still shown as a preclinical company, actually dosed their first patient just in the second week of October. And so we have now placed them in the phase one bracket. And this really is showing that this is a dynamic development of our portfolio. We have actually been in companies that are now in commercial growth when they were in the product development segment. So we are a long-term investor who really is helping these companies to move forward, not just with the money to do their clinical trials, but with our expertise and network to both attract other investors, to make M&A with to basically be acquired or at least collaborate with Big Pharma. And here I can mention a few actually. So, Car Medical, that's in the phase two there, they have actually collaborated with Roche. We have, of course, many other companies like Procarium who've collaborated with large companies. We have companies who have used, for example, the checkpoint inhibitors of other companies in the supply agreement. So, we're always out there helping these companies to create connections. And just a few highlights that are continuously advancing. So, Genius Therapeutics, that's in phase two again. It's a company in the personalized cancer vaccine space for advanced liver cancer. I've spoken about them before in previous quarters. They now are having even more long-term data from their patients. The patients are continuing to survive even though, According to the standard of care, many of them would actually be dead if they hadn't been given this personalized cancer vaccine treatment. We also have Mendes, who's making tremendous progress as well on upscaling their manufacturing together with Northex Biologics, which you see on the right hand side over there in the commercial growth. That's a manufacturing powerhouse that together with Mendes expertise in cell therapy, both companies are gaining a lot of expertise and growing uh their business uh but at the same time helping each other to advance uh the aml maintenance therapy that menders has to a bigger trial that eventually can result in uh in licensure and marketing of a completely new drug that doesn't exist today so uh all in all there's a lot going on in the portfolio and happy to take more questions on this in the q a session